1 Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative

2 study: A systematic review and meta-analysis

- 3
- 4 Tim K. Tsang^{1,2}, Sheena G. Sullivan³, Xiaotong Huang¹, Can Wang¹, Yifan Wang¹,
- 5 Joshua Nealon¹, Bingyi Yang¹, Kylie E. C. Ainslie^{1,4}, Benjamin J. Cowling^{1,2}
- 6

7 Affiliations:

8	1.	WHO Collaborating Centre for Infectious Disease Epidemiology and
9		Control, School of Public Health, Li Ka Shing Faculty of Medicine, The
10		University of Hong Kong, Hong Kong Special Administrative Region, China
11	2.	Laboratory of Data Discovery for Health Limited, Hong Kong Science and
12		Technology Park, New Territories, Hong Kong Special Administrative
13		Region, China
14	3.	WHO Collaborating Centre for Reference and Research on Influenza,
15		Royal Melbourne Hospital, and Doherty Department, University of
16		Melbourne, at the Peter Doherty Institute for Infection and Immunity,
17		Melbourne, Australia
18	4.	Centre for Infectious Disease Control, National Institute for Public Health
19		and Environment (RIVM), Bilthoven, the Netherlands
20		
21	Corre	sponding author:
22	Dr. Ti	m K. Tsang, School of Public Health, Li Ka Shing Faculty of Medicine, The
23	Unive	rsity of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong.
24	Tel: +	352 3917 9715; Fax: +852 3520 1945; email: <u>timtsang@connect.hku.hk</u>

- 25
- 26 Prof. Benjamin J Cowling, School of Public Health, The University of Hong Kong,
- 27 21 Sassoon Road, Pokfulam, Hong Kong.
- 28 Tel: +852 3917 6711; Fax: +852 3520 1945; email: bcowling@hku.hk
- 29
- 30 Word count: (Abstract: 353)
- 31 (Main text: 3,360)
- 32
- 33
- 34

35 ABSTRACT

36	Background: Prior infection with SARS-CoV-2 can provide protection against
37	infection and severe COVID-19. In settings with high pre-existing immunity,
38	vaccine effectiveness (VE) should decrease with higher levels of immunity
39	among unvaccinated individuals. Here, we conducted a systematic review and
40	meta-analysis to understand the influence of prior infection on VE.
41	Methods : We included test-negative design (TND) studies that examined VE
42	against infection or severe disease (hospitalization, ICU admission, or death) for
43	primary vaccination series. To determine the impact of prior infections on VE
44	estimates, we compared studies that excluded or included people with prior
45	COVID-19 infection. We also compared VE estimates by the cumulative incidence
46	of cases before the start of and incidence rates during each study in the study
47	locations, as further measures of prior infections in the community.
48	Findings: We identified 67 studies that met inclusion criteria. Pooled VE among
49	studies that included people with prior COVID-19 infection was lower against
50	infection (pooled VE: 77%; 95% confidence interval (CI): 72%, 81%) and severe
51	disease (pooled VE: 86%; 95% CI: 83%, 89%), compared with studies that
52	excluded people with prior COVID-19 infection (pooled VE against infection:
53	87%; 95% CI: 85%, 89%; pooled VE against severe disease: 93%; 95% CI: 91%,
54	95%). There was a negative correlation between the cumulative incidence of
55	cases before the start of the study and VE estimates against infection (spearman
56	correlation ($ ho$) = -0.32; 95% CI: -0.45, -0.18) and severe disease ($ ho$ = -0.49; 95%
57	CI: -0.64 , -0.30). There was also a negative correlation between the incidence
58	rates of cases during the study period and VE estimates against infection ($ ho$ = -

- 60 Interpretation: Based on a review of published VE estimates we found clear
- 61 empirical evidence that higher levels of pre-existing immunity in a population
- 62 were associated with lower VE estimates. Excluding previously infected
- 63 individuals from VE studies may result in higher VE estimates with limited
- 64 generalisability to the wider population. Prior infections should be treated as
- 65 confounder and effect modificatory when the policies were targeted to whole
- 66 population or stratified by infection history, respectively.
- 67

68 INTRODUCTION

69	COVID-19 vaccines reduce the risk of infection and can also ameliorate disease
70	severity when breakthrough infection occurs $(1, 2)$. Ongoing evaluation of
71	COVID-19 vaccine effectiveness (VE) has largely been measured through
72	observational studies, particularly test-negative design (TND) studies, which
73	share some similarities with case control studies (3). However, there has been
74	substantial variation among reported VE estimates (4-7), which may be
75	attributable to differences in study design, the vaccines used, disease incidence
76	and population characteristics. Importantly, pre-existing population immunity as
77	a result of infection could explain changes in COVID-19 VE over time and among
78	populations (8, 9).
79	
80	Infection with SARS-CoV-2 induces an immune response to protect against

81 reinfection (10-14). However, reinfection could occur due to waning naturally-82 induced immunity (15, 16) or virus evolution (17, 18). Nevertheless, studies 83 have shown that compared to persons with no prior infection, vaccination 84 among people with prior infection enhances neutralising antibody activity as 85 well as cell-mediated responses that can protect against (re)infection (19), 86 suggesting prior infections may modify the protection from vaccinations. In 87 settings where a large proportion of the population has prior exposure through 88 infection, the unvaccinated will be more protected from infection than in a naïve 89 population, thereby diluting the apparent effectiveness of vaccination. Under 90 these two scenarios, prior infection modifies the effect of vaccination 91 (Supplementary note 1).

92

93	Prior infection can also alter people's decision to be vaccinated and present for
94	care. For example, vaccination requirements vary for people with recent prior
95	infection in Hong Kong (20). Moreover, individuals with recent infection may
96	choose not to be vaccinated if they believe they have sufficient pre-existing
97	immunity to prevent re-infection and ameliorate the severity of any re-infections
98	that do occur (21). Additionally, these individuals may also choose not to present
99	for care believing their COVID-like symptoms are due to another illness, leading
100	to differential under-ascertainment of previously-infected COVID-19 cases in
101	surveillance data. Other individual-level factors may also affect the decision to
102	vaccinate and engage in infection-risk behaviors, such as perceived risk of severe
103	disease post-infection (22-24). Acting in this way, prior infection may create a
104	confounding bias along of the vaccination-COVID-19 association (Supplementary
105	note 1).
106	

- 107 Here, we aim to review systematically and meta-analyse published data to
- 108 characterize the potential impact of pre-existing population immunity on VE
- 109 estimates for completed primary vaccination series of COVID-19. We also
- 110 conducted meta-regression to account for the influence of key design features
- 111 such as vaccine types, circulating virus strains.
- 112

113 **METHODS**

- 114 Search strategy and selection criteria
- 115 This systematic review was conducted following the Preferred Reporting Items
- 116 for Systematic Review and Meta-analysis (PRISMA) statement (25). A
- 117 standardized search was done in PubMed, Embase and Web of Science, using the

118	search term "("test negative" OR "effectiveness") AND ("vaccine") AND ("COVID-
119	19" OR "SARS-CoV-2")". The search was done on 11 July 2022, with no language
120	restrictions. Additional relevant articles from the reference sections of identified
121	articles were also reviewed. Two authors (XH and CW) independently screened
122	the titles and full texts, and extracted data from the included studies, with
123	disagreement resolved by consensus together with a third author (TKT). Studies
124	identified from different databases were de-duplicated.
125	
126	Studies that reported using a test-negative approach in which all cases and non-
127	cases were tested were included (26, 27). We included published TND studies
128	with participants recruited from the general population, and reported estimates
129	of VE for completed primary vaccination series (two doses for most vaccines;
130	one dose for Janssen) against at least one of the following endpoints: 1) positive
131	test result, 2) symptomatic disease, 3) hospitalization, 4) ICU admission, 5)
132	severe COVID, 6) death. We excluded articles if: 1) the study participants were
133	recruited from a specific sub-population, such as healthcare professionals; 2)
134	studies that only reported VE for booster doses; 3) studies that summarised or
135	re-analysed already-published data; 4) studies that only reported pooled VE
136	estimates for different vaccines; 5) the study was a preprint; or 6) the full text
137	was not available.
138	
139	Data were extracted from included studies using a standardised data collection

form (Table S1) that collected information about: 1) study period; 2) region(s); 3)

- 141 population; 4) the use of clinical criteria for enrolment; and 5) whether
- 142 participants with prior SARS-CoV-2 infection were included. For each study, VE

143	estimates with confidence intervals were extracted separately for each endpoint
144	(e.g. infection, hospitalisation), vaccine and the circulating virus. In some studies,
145	VEs specific to time intervals after vaccination were reported. Therefore, we
146	extracted VE estimates for the first available time interval at least 14 days post-
147	vaccination, because antibodies have been shown to peak by then in naïve
148	persons (28). For studies that reported multiple estimates, such as by age group
149	or type of vaccine, all subgroup-specific estimates were included, but the overall
150	estimates were excluded.
151	
152	Meta-analysis
153	In all identified studies, VE was defined as $100\%*(1\text{-}OR)$. The extracted VE
154	estimates were meta-analysed to estimate pooled VE. VE estimates were
155	transformed to the odds ratios scale, meta-analysed, then back-transformed to
156	the VE scale for interpretation. The pooled odds ratio was estimated by random
157	effects meta-analyses using the inverse variance method and restricted
158	maximum likelihood estimator for heterogeneity (29-32). Heterogeneity was
159	assessed using Cochran's Q and the I^2 statistic (33). We considered an I^2 value
160	more than 75% to be indicative of high heterogeneity (34). We also conducted a
161	sensitivity analysis using fixed effects meta-analyses.

162

163 The main study feature of interest was if pooled VE against infection or severe

164 disease varied depending on whether the studies included or excluded

165 participants with prior infection. Severe disease was based on whether the

166 estimate was limited to cases who required hospitalization, ICU admission and

167 death. Otherwise the estimate was classified as VE against infection, which

168 included estimates of VE against test positive or symptomatic infection (without

169 hospitalisation).

170

171	Pooled estimates were additionally disaggregated by the probable circulating
172	virus and vaccine administered. Most studies did not report variant-specific VE
173	estimates but did report study periods and the general prevalence of variants
174	during that period. Therefore, estimates were grouped according to the
175	predominant circulating virus: 1) Omicron, 2) late-Delta, which was the period
176	with co-circulation of Delta and Omicron, 3) Delta, 4) pre-Delta, which included
177	ancestral strains and variants preceding Delta. Type of vaccine was grouped as
178	follows: 1) mRNA vaccines, including vaccines produced by Moderna and Pfizer-
179	BioNTech; 2) Adenovirus vector vaccines, including vaccine produced by
180	AstraZeneca, Janssen and Gamaleya; and 3) Inactivated virus vaccines, including
181	vaccine produced by Sinovac Biotech and Sinopharm.
182	

183 Meta-regression

184 To evaluate the impact of pre-existing immunity on VE estimates, we used a

185 meta-regression approach. Three proxies of prior immunity were explored: 1)

inclusion versus exclusion of participants with prior infection; 2) cumulative

187 incidence of COVID-19 since December 2019 in each of the study

188 countries/regions before the start of study; and 3) the incidence rate of COVID-

189 19 in the country/region during the study period. For this, we downloaded

190 population denominator data and daily COVID-19 case data from the World

191 Health Organization website (35, 36). We first used correlation analysis,

including Pearson (r) and Shearman (ρ) correlation coefficient, to determine the

193	association between pre-existing immunity and VE estimates. Meta-regression
194	models were adjusted for age group (age below or above 65 years), types of
195	vaccines used, predominant circulating virus, and the use of clinical criteria for
196	enrolment. A sensitivity analysis was conducted for additionally adjusting for
197	location and duration of the study.
198	
199	The fitted meta-regression model estimated the ratio of ORs (ROR) for each of
200	the prior immunity proxies explored. On the OR scale, values closer to $f 0$
201	indicated a more effective vaccine, while values closer to 1 indicated a less
202	effective vaccine. This was counter to the VE scale where values closer to 0
203	indicated an ineffective vaccine. Therefore, using inclusion versus exclusion of
204	participants with prior infection as an example, if ROR > 1, then the OR estimated
205	from studies including participants with prior infection was higher than that
206	from studies excluding participants with prior infection. On the VE scale, this
207	translates to lower VE for studies that included participants with prior infection
208	than studies that excluded these participants.
209	
210	We plotted the expected change in VE estimate to visualize the impact of each
211	prior immunity proxy based on the ROR obtained from meta-regression. To
212	illustrate the change in VE scale, we showed the change in estimate based on the
213	ROR assuming VE for the reference group of 80% against infection and 90% $$
214	against severe disease. Statistical analyses were conducted using R version 4.0.5
215	(R Foundation for Statistical Computing, Vienna, Austria).
216	

217 **RESULTS**

218	We identified 6904 studies, among which 2929 were duplicates. Title and
219	abstract screening of the remaining articles identified 480 for full text review, of
220	which 67 met our inclusion criteria (4-7, 37-99) (Figure 1; Table S2). Studies
221	were set in 17 countries/regions. Most were from the United States (29) and
222	United Kingdom (10). Fifty-one studies provided 173 VE estimates against
223	infection (Figure S1-2), and 41 studies provided 93 estimates against severe
224	disease (Figure S3-4). Among all 67 studies, 45 included and 24 studies excluded
225	participants with prior COVID-19 infection (including two studies which
226	provided VE estimates including and excluding participants with COVID-19
227	infection). A summary of study characteristics and the corresponding number of
228	estimates, including handling of participants with prior infections, enrolment
229	criteria, vaccine types and circulating virus are provided in Table \$3-\$5.
230	
231	Vaccine effectiveness against infection and severe disease
232	The $173~VE$ point estimates against infection ranged from 14% to 98% , with
233	I ² =100%, indicating high heterogeneity (Figure 2-3). Among them, 95 (55%)
234	were higher than 80%. The 93 point estimates against severe disease were also
235	highly heterogeneous (I ² =100%), ranging from 20% to 100% (Figure 2-3).
236	Among them, 71 (76%) were higher than 80%. For both outcomes, we observed
237	declining VE over time from early 2021 to mid 2022 (Figure S5).
238	
239	Impact of type of vaccine and circulating viruses
240	Our meta-analysis (Figure 3) indicated that pooled VE against infection for a

primary course of mRNA vaccines was 86% (95% CI: 84%, 88%), compared to

242	69% (95% CI: 64%, 73%) for adenovirus vector vaccines and 67% (95% CI: 34%,
243	84%) for inactivated virus vaccines. When we examined differences in pooled VE
244	by the circulating virus, we found that VE against infection during the Omicron
245	period was far lower (VE: 52%; 95% CI: 45%, 59%) than during the pre-Delta
246	(VE: 89%; 95% CI: 87%, 91%), Delta (VE: 78%; 95% CI: 58%, 88%), and the late-
247	Delta periods (VE: 79%; 95% CI: 74%, 92%) . Similarly, VE against severe
248	disease during the Omicron period was 64% (95% CI: 56% , 71%), which was
249	lower than for pre-Delta (VE: 92%; 95% CI: 89%, 94%), Delta (VE: 87%; 95% CI:
250	76%, 93%), and late-Delta periods (VE: 91%; 95% CI: 88%, 93%). The results
251	were similar when further disaggregated by including or excluding prior
252	infection (Table S8), or using fixed-effects analysis (Figure S6).
253	
254	Role of prior infection on VE estimates
255	In general, we found that VE estimates derived from study participants with

- lower pre-existing immunity were higher. The pooled VE against infection for
- studies that excluded participants with prior COVID-19 infection was higher (VE:
- 258 87%; 95% CI: 85%, 89%) than from studies that included these participants (VE:
- 259 77%: 95% CI: 72%, 81%). Similarly, pooled VE against severe disease from
- studies that excluded participants with prior COVID-19 infection (VE: 93%; 95%)
- CI: 91%, 95%) was higher than from studies that included these participants (VE:
- 262 87%: 95% CI: 84%, 90%). There was high heterogeneity among the estimates (I² >
- 263 99%). The pooled estimates from fixed-effect analysis were similar (Figure S6).

264

- 265 In meta-regression adjusting for vaccine type, circulating virus, and enrolment
- 266 criteria (Table S6; Figure 4A-B), the OR against infection from studies that

267	included participants with prior COVID-19 infection (higher pre-existing
268	immunity) was 1.56-fold higher (95% CI: 1.29, 1.89) than the OR from studies
269	that excluded these participants (i.e. with generally lower pre-existing
270	immunity). Therefore, the VE against infection in a study that originally excluded
271	participants with prior COVID-19 infection was 80%, it would be expected to
272	yield an estimate of 69% (95% CI: 62%, 74%) had they included those
273	participants. Similarly, the OR against severe disease from studies that included
274	participants with prior COVID-19 infection was 1.73-fold higher (95% CI: 1.23,
275	2.45) than from studies that excluded these participants. Assuming a baseline VE
276	against severe disease of 90%, the corresponding VE expected when participants
277	with prior infection were included would be 83% (95% CI: 76%, 87%). The
278	results were similar with adjustment for location and duration of study (Table
279	S7).

280

281 Impact of cumulative incidence

282 There was a modest, negative correlation between the cumulative incidence of

283 cases in the study locations prior to the start of the study, as a proxy of pre-

existing population immunity (Figure S8), and VE against infection (Pearson

285 correlation (*r*) = -0.42; 95% CI: -0.54, -0.30; Shearman correlation (ρ) = -0.32; 95%

286 CI: -0.45, -0.18) and severe disease (r = -0.41, 95% CI: -0.56, -0.22; $\rho = -0.49$; 95%

287 CI: -0.64, -0.30). In meta-regression, adjusting for vaccine type, circulating virus,

and enrolment criteria (Table S6; Figure 4A-B), the ROR against infection

associated with a doubling of the cumulative incidence of cases before the start

- of studies was 1.10 (95% CI: 1.02, 1.20). Therefore, if the baseline VE against
- infection from a study was 80%, then the corresponding VE for a setting with

292	twice the cumulative incidence of cases before the start of a study would
293	represent a two-percentage point reduction in VE (VE=78%; 95% CI: 76%, 79.6%
294	for a doubling). The ROR against severe disease for each doubling of the
295	cumulative incidence of cases before the start of a study (higher pre-existing
296	immunity) was 1.47 (95% CI: 1.26, 1.71). Therefore, assuming a baseline VE
297	against severe diseases of 90%, the corresponding VE for a setting with twice the
298	cumulative incidence of cases before the start of a study would represent a 5
299	percentage point drop in VE (VE=85%, 95% CI: 83%, 87% for the initial
300	doubling).

301

302 Impact of incidence rate during the study period

- 303 There was a modest, negative correlation between the incidence rates of cases in
- 304 the study locations prior to the start of the study, as a proxy of pre-existing
- 305 population immunity (Figure S8), and VE against infection (r = -0.38; 95% CI: -
- 306 0.50, -0.24; ρ = -0.48; 95% CI: -0.59, -0.34) and severe disease (*r* = -0.50, 95% CI:

 $307 - 0.64, -0.33; \rho = -0.42; 95\%$ CI: -0.58, -0.23). After adjusting for vaccine type,

- 308 circulating virus and enrolment criteria (Table S6), we estimated that the ROR
- 309 against infection for each doubling of the incidence of cases during the study
- period was 1.16 (95% CI: 1.07, 1.25). If the baseline VE against infection from a
- 311 study was 80%, then the corresponding VE from a study with twice the incidence
- of cases during the study period would be 77% (95% CI: 75%, 79%). We also
- estimated that the ROR against severe disease associated with a doubling in the
- incidence of cases and death during the study was 1.20 (95% CI: 1.03, 1.40).
- Therefore, assuming a baseline VE of 90% against severe disease, the

316 corresponding VE for a study with twice as many cases during the study period

317 would be 88% (95% CI: 86%, 89.7%).

318

319 **DISCUSSION**

320 In this study, we summarized VE estimates from TND studies to understand the

321 impact of prior infections on VE estimates. We found that higher pre-existing

322 immunity in the source population, indicated by including participants with

323 prior COVID-19 infection, higher pre-study cumulative incidence of cases, and

324 higher incidence rate of cases during study period, was associated with lower VE.

325

326	Prior infection could be a confounder, effect modifier or both. As a confounder it
327	could affect peoples' decisions to vaccinate and modify their risk behaviours as
328	well as providing protection against reinfection (12, 13, 21). Hence, the VE
329	obtained from individuals with or without prior infection would be similar, if the
330	influence of the confounding could be controlled in analysis. On the other hand, if
331	prior infection were only an effect modifier (i.e. only associated with the risk of
332	(re)infection and not the propensity to be vaccinated) vaccination in settings
333	with higher pre-existing immunity would appear to have a relatively modest
334	effect on further increasing protection at the population level because VE would
335	be lower among previously infected participants (12, 13). In reality prior
336	infection is probably both a confounder and effect modifier and therefore studies
337	should consider both appropriate confounding control, such as through
338	covariate adjustment or stratification, as well as inclusion of interaction terms to
339	explore the potential effect modification.

340

341	When VE was estimated based on studies excluding participants with prior
342	infection, these VE estimates should be interpreted as the VE for a hypothetical
343	population with no pre-existing immunity. As of late 2022, these estimates
344	would have limited practical value in most locations which have experienced
345	substantial epidemics. Epidemic forecasting models used to inform public health
346	control policies should separate individuals into different compartments based
347	on infection history to improve the precision of their forecasts. Therefore, groups
348	estimating VE estimates to inform policy should stratify by infection history so
349	that their work will be more broadly useful for policy (100, 101).
350	
351	Our observation that higher incidence rates during a study period were
352	associated with lower VE estimates suggests that SARS-CoV-2 vaccines provide
353	leaky protection (102), since the VE depended on the number of exposure
354	(proxied by incidence rates during study period) . It has previously been shown
355	that the ORs derived from TND studies were biased (103), so that VE estimates
356	for leaky vaccines would decrease with time since vaccination, even if the true
357	VE remained unchanged (102). For COVID vaccines, the antigenic drift observed
358	for SARS-CoV-2 viruses makes it difficult to disentangle reduced VE associated
359	with a leaky vaccine from reduced VE associated with vaccine antigenic match,
360	and a decreased proportion of susceptible in the community.
361	
362	Although 55% of VE estimates against infection and 76% of estimates against
363	severe disease were higher than 80% , heterogeneity was very high, as indicated
364	by the high I^2 values observed. Consistent with previous reviews, high
365	heterogeneity could be attributed to differences in effectiveness among vaccine

366	types, or the predominant circulating virus in each study (8, 105). However, we
367	continued to observe high heterogeneity when estimating pooled VE against
368	specific vaccine types and the predominant virus. Our meta-regression identified
369	some sources of the heterogeneity, such as pre-existing immunity. However,
370	heterogeneity remained high and further investigation is needed to identify
371	other causes to ensure valid VE estimates are available for ongoing optimization
372	of vaccination strategies (106).
373	
374	Our study had some limitations. First, our review focused on VE of primary
375	vaccination series. Further analysis would be required to determine whether

376 similar issues apply to estimation of VE for booster doses, which are complicated

377 by dosing schedules that mix vaccine types, the number of doses received,

378 greater antigenic differences between the vaccines received and the dominant

379 circulating virus, changes in vaccine formulation including bivalent formulations,

and the accumulation of immunity through both vaccination and infection over

time. Second, most studies were conducted in adults, so that our results may not

382 be generalizable to children. Finally, TND studies included in our review were

383 observational in nature. Some confounders were adjusted in these studies,

including age, sex, being health care workers, or pre-existing conditions.

385 However, we did not include a bias assessment to evaluate whether studies

386 adequately addressed confounding nor have we considered other potential

387 sources of bias such as measurement errors.

388

In conclusion, we observed reduced VE associated with higher pre-existing
immunity in the population. Exclusion of participants with prior infection could

391	artificially inflate VE estimates and affect their generalisability to the wider
392	population. If the goal of a study is to inform policy that applies to the whole
393	population, participants with prior infection should be included and their status
394	included as a covariate for confounder control. However, if decision-makers
395	desire different vaccination policies dependent on infection history then studies
396	need to stratify accordingly, or including interaction term, instead of excluding
397	participants with prior infection. Studies unable to adjust for prior infection
398	could consider using external adjustment (107) to assess the potential effect of
399	this confounder on their estimates. Optimal design of VE studies remains a
400	research priority. In particular, further work is needed to understand how prior
401	infection influences VE for booster doses and as vaccine formulations change.
402	

404 **ACKNOWLEDGEMENTS**

405	The authors thank Hang Qi for technical assistance. This project was supported
406	by the National Institute of General Medical Sciences (grant no. R01 GM139926),
407	and the Theme-based Research Scheme (Project No. T11-712/19-N) of the
408	Research Grants Council of the Hong Kong SAR Government. BJC is supported by
409	an RGC Senior Research Fellowship (grant number: HKU SRFS2021-7S03) and
410	the AIR@innoHK program of the Innovation and Technology Commission of the
411	Hong Kong SAR Government. The WHO Collaborating Centre for Reference and
412	Research on Influenza is supported by the Australian Government Department of
413	Health and Aged Care.

414

415 **COMPETING INTERESTS STATEMENT**

- 416 BJC reports honoraria from AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna,
- 417 Pfizer, Roche and Sanofi Pasteur. JN was previously employed by and owns
- 418 stocks in Sanofi. The authors report no other potential conflicts of interest.
- 419
- 420
- 421

422 **REFERENCES**

- 423 1. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19
- 424 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med.
- 425 2021;385(16):1474-84.
- 426 2. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2
- 427 breakthrough infections in vaccinated individuals: measurement, causes and
- 428 impact. Nat Rev Immunol. 2022;22(1):57-65.
- 429 3. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm
- 430 MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic
- 431 review and meta-analysis of test-negative design studies. Lancet Infect Dis.
- 432 2016;16(8):942-51.
- 433 4. Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al.
- 434 Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of
- 435 SARS-CoV-2: test negative case-control study. Bmj. 2021;375:e068848.
- 436 5. Andrews1 N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al.
- 437 Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J
- 438 Med. 2022.
- 439 6. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al.
- 440 Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
- 441 Nat Med. 2022.
- 442 7. Chemaitelly2 H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan
- 443 MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and
- 444 B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med.
- 445 2021;27(9):1614-21.

446	8.	Higdon MM,	Wahl B,	Jones CB,	Rosen [G	, Truelove	SA, Baid	ya A, et al. A
		<i>c</i> , <i>, ,</i>	,	, ,	, ,			/ /

- 447 Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and
- 448 Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2
- 449 Infection and Disease. Open Forum Infect Dis. 2022;9(6):ofac138.
- 450 9. Lewnard JA, Patel MM, Jewell NP, Verani JR, Kobayashi M, Tenforde MW,
- 451 et al. Theoretical Framework for Retrospective Studies of the Effectiveness of
- 452 SARS-CoV-2 Vaccines. Epidemiology. 2021;32(4):508-17.
- 453 10. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and
- 454 immune responses. J Med Virol. 2020;92(4):424-32.
- 455 11. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ,
- 456 et al. Neutralizing and protective human monoclonal antibodies recognizing the
- 457 N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184(9):2316-31
- 458 e15.
- 459 12. Kojima N, Shrestha NK, Klausner JD. A Systematic Review of the
- 460 Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection. Eval Health
 461 Prof. 2021;44(4):327-32.
- 462 13. Leidi A, Koegler F, Dumont R, Dubos R, Zaballa ME, Piumatti G, et al. Risk
- 463 of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome
- 464 Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched
- 465 Cohort Study. Clin Infect Dis. 2022;74(4):622-9.
- 466 14. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment
- 467 of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested
- 468 individuals in Denmark in 2020: a population-level observational study. Lancet.
- 469 2021;397(10280):1204-12.

470	15. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody
471	responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.
472	16. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
473	memory to SARS-CoV-2 assessed for up to 8 months after infection. Science.
474	2021;371(6529).
475	17. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C,
476	Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with
477	emergence of Omicron in South Africa. Science. 2022;376(6593):eabn4947.
478	18. Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The
479	durability of immunity against reinfection by SARS-CoV-2: a comparative
480	evolutionary study. Lancet Microbe. 2021;2(12):e666-e75.
481	19. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al.
482	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first
483	vaccine dose. Science. 2021.
484	20. The Government of the Hong Kong Special Administrative Region. Vaccine
485	pass, <u>https://www.coronavirus.gov.hk/eng/vaccine-pass.html</u> (accessed Aug 26,
486	2022) [
487	21. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public
488	Health. 2021;194:245-51.
489	22. Robinson E, Jones A, Lesser I, Daly M. International estimates of intended
490	uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-
491	analysis of large nationally representative samples. Vaccine. 2021;39(15):2024-
492	34.
493	23. Parker DM, Bruckner T, Vieira VM, Medina C, Minin VN, Felgner PL, et al.
494	Predictors of Test Positivity, Mortality, and Seropositivity during the Early

- 495 Coronavirus Disease Epidemic, Orange County, California, USA. Emerg Infect Dis.
- 496 2021;27(10):2604-18.
- 497 24. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.
- 498 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med.
- 499 2021;385(10):875-84.
- 500 25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
- 501 systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
- 502 2009;6(7):e1000097.
- 503 26. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the
- 504 Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness.
- 505 Am J Epidemiol. 2016;184(5):345-53.
- 506 27. Jackson ML, Nelson JC. The test-negative design for estimating influenza
- 507 vaccine effectiveness. Vaccine. 2013;31(17):2165-8.
- 508 28. Yang B, Huang X, Gao H, Leung NH, Tsang TK, Cowling BJ. Immunogenicity,
- 509 efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic
- review and meta-analysis. BMC Med. 2022;20(1):409.
- 511 29. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis.
- 512 Psychological Methods. 1998;3(4):486-504.
- 513 30. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E,
- 514 et al. A comparison of heterogeneity variance estimators in simulated random-
- effects meta-analyses. Res Synth Methods. 2019;10(1):83-98.
- 516 31. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a
- 517 comparison of methods. Stat Med. 1999;18(20):2693-708.

- 518 32. Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, et al.
- 519 Methods to calculate uncertainty in the estimated overall effect size from a
- 520 random-effects meta-analysis. Res Synth Methods. 2019;10(1):23-43.
- 521 33. Cochran WG. The combination of estimates from different experiments.
- 522 Biometrics 1954;10:101-29.
- 523 34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
- 524 meta-analyses. Bmj. 2003;327(7414):557-60.
- 525 35. World Health Organization. Daily cases and deaths by date reported to
- 526 WHO [Available from: https://covid19.who.int/WHO-COVID-19-global-data.csv.
- 527 36. World Health Organization. COVID-19 Explorer [Available from:
- 528 <u>https://worldhealthorg.shinyapps.io/covid/</u>.
- 529 37. Abu-Raddad1 LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM,
- Al Khatib HA, et al. Waning of mRNA-1273 vaccine effectiveness against SARS-
- 531 CoV-2 infection in Qatar. N Engl J Med. 2022;16.
- 532 38. Abu-Raddad2 LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2
- 533 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med.
- 534 2021;385(2):187-9.
- 535 39. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et
- al. Serological responses and vaccine effectiveness for extended COVID-19
- 537 vaccine schedules in England. Nat Commun. 2021;12(1):7217.
- 538 40. Andrejko KL, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, et al.
- 539 Prevention of COVID-19 by mRNA-based vaccines within the general population
- of California. Clin Infect Dis. 2021.

- 541 41. Andrews 2 N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al.
- 542 Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
- 543 New England Journal of Medicine. 2022;386(4):340-50.
- 42. Bernal1 JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
- 545 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New
- 546 England Journal of Medicine. 2021;385(7):585-94.
- 43. Bernal2 JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.
- 548 Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-
- 549 19 related symptoms, hospital admissions, and mortality in older adults in
- 550 England: Test negative case-control study. The BMJ. 2021;373 (no pagination).
- 551 44. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al.
- Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by
- 553 Time Since Vaccination and Delta Variant Predominance. Jama.
- 554 2022;327(11):1032-41.
- 555 45. Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 Vaccine
- 556 Effectiveness in a High-Risk National Population in a Real-World Setting. Ann
- 557 Intern Med. 2021;174(10):1404-8.
- 558 46. Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R,
- 559 Júnior JB, Paixão ES, et al. Vaccine effectiveness of heterologous CoronaVac plus
- 560 BNT162b2 in Brazil. Nat Med. 2022.
- 561 47. Chemaitelly1 H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane
- 562 FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection
- 563 in Qatar. N Engl J Med. 2021;385(24):e83.
- 564 48. Chung1 H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al.
- 565 Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against

- 566 symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario,
- 567 Canada: test negative design study. Bmj. 2021;374:n1943.
- 568 49. Chung2 JR, Kim SS, Belongia EA, McLean HQ, King JP, Nowalk MP, et al.
- 569 Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged >=12
- 570 Years with Reported Contact with COVID-19 Cases, February September 2021.
- 571 Influenza Other Respi Viruses. 2022:1-7.
- 572 50. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of
- 573 BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med.
- 574 2022;386(5):494-6.
- 575 51. Corrao G, Franchi M, Rea F, Cereda D, Barone A, Borriello CR, et al.
- 576 Protective action of natural and induced immunization against the occurrence of
- delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control
- 578 study. BMC Med. 2022;20(1):52.
- 579 52. Drawz PE, DeSilva M, Bodurtha P, Benitez GV, Murray A, Chamberlain AM,
- et al. Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for
- 581 SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide
- 582Report from the Minnesota Electronic Health Record Consortium. Clin Infect Dis.
- **583 2022**.
- 584 53. Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al.
- 585 Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against
- 586 COVID-19-associated hospitalizations among immunocompromised adults Nine
- 587 States, January-September 2021. American Journal of Transplantation.
- 588 2022;22(1):306-14.
- 589 54. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al.
- 590 Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-

591	Associated Emergency	Department and	Urgent Care I	Encounters and
		1	0	

- 592 Hospitalizations Among Adults During Periods of Delta and Omicron Variant
- 593 Predominance VISION Network, 10 States, August 2021-January 2022. MMWR
- 594 Morb Mortal Wkly Rep. 2022;71(7):255-63.
- 595 55. Grannis SJ, Rowley EA, Ong TC, Stenehjem E, Klein NP, DeSilva MB, et al.
- 596 Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-
- 597 Associated Emergency Department or Urgent Care Clinic Encounters and
- 598 Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant
- 599 Predominance Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep.
- 600 2021;70(37):1291-3.
- 601 56. Hitchings MDT, Ranzani OT, Dorion M, D'Agostini TL, de Paula RC, de
- Paula OFP, et al. Effectiveness of ChAdOx1 vaccine in older adults during SARS-
- 603 CoV-2 Gamma variant circulation in São Paulo. Nat Commun. 2021;12(1):6220.
- 604 57. Kim SS, Chung JR, Belongia EA, McLean HQ, King JP, Nowalk MP, et al.
- 605 mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients
- 606 Aged ≥ 16 Years in the United States, February May 2021. J Infect Dis. 2021.
- 607 58. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et

al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from

- omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective
- 610 observational study. Bmj. 2022;376:e069761.
- 611 59. Lewis NM, Naioti EA, Self WH, Ginde AA, Douin DJ, Talbot HK, et al.
- 612 Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age
- and burden of chronic medical conditions among immunocompetent US adults,
- 614 March-August 2021. J Infect Dis. 2021.

- 615 60. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of
- 616 inactivated SARS-CoV-2 vaccines against the Delta variant infection in
- 617 Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect.
- 618 2021;10(1):1751-9.
- 619 61. Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, et al.
- 620 Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2
- 621 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-
- 622 time Surveillance for SARS-CoV-2 (VERSUS). Clinical Infectious Diseases.
- 623 2022;23.
- 624 62. Mallow C, Ferreira T, Shukla B, Warde P, Sosa MA, Parekh DJ, et al. Real
- 625 world SARS-COV-2 vaccine effectiveness in a Miami academic institution. Am J
- 626 Emerg Med. 2022;54:97-101.
- 627 63. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al.
- 628 Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection
- and severe outcomes with variants of concern in Ontario. Nat Microbiol.
- 630 2022;7(3):379-85.
- 631 64. Ngyen LBL, Bauer R, Lesieur Z, Galtier F, Duval X, Vanhems P, et al.
- 632 Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test
- 633 negative case control study. Infectious Diseases Now. 2022;52(1):40-3.
- 634 65. Olson1 SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al.
- 635 Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19
- 636 Hospitalization Among Persons Aged 12-18 Years United States, June-
- 637 September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(42):1483-8.

- 638 66. Olson 2 SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al.
- 639 Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. N
- 640 Engl J Med. 2022;386(8):713-23.
- 641 67. Pardo-Seco J, Mallah N, López-Pérez LR, González-Pérez JM, Rosón B,
- 642 Otero-Barrós MT, et al. Evaluation of BNT162b2 Vaccine Effectiveness in Galicia,
- 643 Northwest Spain. Int J Environ Res Public Health. 2022;19(7).
- 644 68. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al.
- 645 BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
- 646 N Engl J Med. 2022.
- 647 69. Ranzani1 O, Hitchings MDT, Dorion M, D'Agostini TL, de Paula RC, de
- 648 Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a
- 649 gamma variant associated epidemic of covid-19 in Brazil: test negative case-
- 650 control study. Bmj-British Medical Journal. 2021;374.
- 651 70. Ranzani2 OT, Silva AAB, Peres IT, Antunes BBP, Gonzaga-da-Silva TW,
- 652 Soranz DR, et al. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in
- a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design
- 654 study. Clin Microbiol Infect. 2022.
- 655 71. Rearte A, Castelli JM, Rearte R, Fuentes N, Pennini V, Pesce M, et al.
- 656 Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for
- risk of infection with SARS-CoV-2 and death due to COVID-19 in people older
- 658 than 60 years in Argentina: a test-negative, case-control, and retrospective
- 659 longitudinal study. Lancet. 2022;399(10331):1254-64.
- 660 72. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al.
- 661 Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &
- 662 Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults

- 663 Without Immunocompromising Conditions United States, March-August 2021.
- 664 MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-43.
- 665 73. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
- 666 Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
- 667 Lancet. 2021;397(10293):2461-2.
- 668 74. Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P,
- 669 Suwantarat N, Satdhabudha A, et al. Comparing real-life effectiveness of various
- 670 COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-
- 671 negative case-control study. Emerg Microbes Infect. 2022;11(1):585-92.
- 672 75. Tabak YP, Sun X, Brennan TA, Chaguturu SK. Incidence and Estimated
- 673 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among
- 674 Persons Tested in US Retail Locations, May 1 to August 7, 2021. JAMA Netw Open.
- 675 2021;4(12):e2143346.
- 676 76. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib
- 677 HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the
- 678 SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136-43.
- 679 77. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al.
- 680 Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19
- 681 Among Hospitalized Adults Aged ≥65 Years United States, January-March 2021.
- 682 MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9.
- 683 78. Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S,
- 684 Sivasubbu S, et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-
- 685 2 infection during the delta (B.1.617.2) variant surge in India: a test-negative,
- 686 case-control study and a mechanistic study of post-vaccination immune
- 687 responses. Lancet Infect Dis. 2022;22(4):473-82.

- 688 79. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al.
- 689 Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N
- 690 Engl J Med. 2021;385(15):1355-71.
- 691 80. Winkelman TNA, Rai NK, Bodurtha PJ, Chamberlain AM, DeSilva M, Jeruzal
- J, et al. Trends in COVID-19 Vaccine Administration and Effectiveness Through
- 693 October 2021. JAMA Netw Open. 2022;5(3):e225018.
- 694 81. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et
- al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against
- 696 Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18
- 697 Years United States, July-December 2021. MMWR Morb Mortal Wkly Rep.
- 698 2022;71(2):52-8.
- 699 82. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM,
- et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron
- 701 Infections. N Engl J Med. 2022;387(1):21-34.
- 702 83. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al.
- 703 Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms,
- hospitalization and death in England. Nature Medicine. 2022;28(4):831-+.
- 705 84. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al.
- 706 Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and
- 707 BA.2 subvariants in Qatar. Nat Commun. 2022;13(1):3082.
- 708 85. Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al.
- 709 Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against
- 710 COVID-19-Associated Hospitalizations Among Immunocompromised Adults -
- 711 Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep.
- 712 2021;70(44):1553-9.

- 713 86. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK,
- et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic
- 715 SARS-CoV-2 Infection in Children and Adolescents During Omicron
- 716 Predominance. Jama-Journal of the American Medical Association.
- 717 87. Husin M, Tok PSK, Suah JL, Thevananthan T, Tng BH, Peariasamy KM, et al.
- 718 Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection
- among adolescents (12 to 17-year-olds) in Malaysia. Int J Infect Dis.
- 720 2022;121:55-7.
- 721 88. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al.
- 722 COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
- 723 Lancet Infect Dis. 2022;22(7):931-3.
- 724 89. Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, et al.
- 725 Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for
- 726 Preventing COVID-19 Hospitalizations and Progression to High Disease Severity
- in the United States. Clin Infect Dis. 2022.
- 728 90. Nadeem I, ul Munamm SA, Rasool MU, Fatimah M, Abu Bakar M, Rana ZK,
- 729 et al. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly
- 730 population of Faisalabad district of Pakistan. Postgraduate Medical Journal.
- 731 91. Niessen FA, Knol MJ, Hahne SJM, Bonten MJM, Bruijning-Verhagen PCJL,
- 732 Peters V, et al. Vaccine effectiveness against COVID-19 related hospital admission
- in the Netherlands: a test-negative case-control study. Vaccine. 2022;10.
- 734 92. Powell AA, Kirsebom F, Stowe J, McOwat K, Saliba V, Ramsay ME, et al.
- 735 Effectiveness of BNT162b2 against COVID-19 in adolescents. Lancet Infect Dis.
- 736 2022;22(5):581-3.

737	03	Skowronski DM	Febriani V	Aughte M	Satavacho	TOR S	Fl Adam S	Zou M	ρt
/3/	<i>7</i> 3.	SKOWTOHSKI DM	, rebriani i,	, OUAKKI M	, setayesne	di J,	EI AUAIII S,	, Lou M,	, et

- al. Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- 739 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals:
- 740 Test-Negative Design Studies From British Columbia and Quebec, Canada.
- 741 Clinical Infectious Diseases.
- 742 94. Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine effectiveness and
- 743 duration of protection against symptomatic infections and severe Covid-19
- outcomes in adults aged 50 years and over, France, January to mid-December
- 745 **2021**. Glob Epidemiol. 2022;4:100076.
- 746 95. Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine-induced and naturally-
- 747 acquired protection against Omicron and Delta symptomatic infection and
- severe COVID-19 outcomes, France, December 2021 to January 2022. Euro
- 749 Surveill. 2022;27(16).

750 96. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al.

- 751 Durability of BNT162b2 vaccine against hospital and emergency department
- admissions due to the omicron and delta variants in a large health system in the
- USA: a test-negative case-control study. Lancet Respir Med. 2022;10(7):689-99.
- 754 97. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al.
- 755 Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger
- 756 RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the
- 757 United States. Clin Infect Dis. 2022;74(9):1515-24.
- 758 98. Tenforde MW, Self WH, Zhu Y, Naioti EA, Gaglani M, Ginde AA, et al.
- 759 Protection of mRNA vaccines against hospitalized COVID-19 in adults over the
- first year following authorization in the United States. Clin Infect Dis. 2022.

- 761 99. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Pillai PS, et al.
- 762 Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and
- immune response amongst individuals in clinical risk groups. Journal of Infection.
- 764 2022;84(5):675-83.
- 765 100. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al.
- 766 Model-informed COVID-19 vaccine prioritization strategies by age and
- 767 serostatus. Science. 2021;371(6532):916-21.
- 768 101. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, et al. Modeling transmission of
- 769 SARS-CoV-2 Omicron in China. Nat Med. 2022.
- 102. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine
- 771 Direct Effects Under the Test-Negative Design. Am J Epidemiol.
- 772 2018;187(12):2686-97.
- 103. Halloran ME, Longini IM, Jr., Struchiner CJ. Design and interpretation of
- vaccine field studies. Epidemiol Rev. 1999;21(1):73-88.
- 775 104. Trogen B, Caplan A. Risk Compensation and COVID-19 Vaccines. Ann
- 776 Intern Med. 2021;174(6):858-9.
- 105. Khandker SS, Godman B, Jawad MI, Meghla BA, Tisha TA, Khondoker MU,
- et al. A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness,
- and Issues. Vaccines (Basel). 2021;9(12).
- 780 106. Singh JA, Upshur REG. The granting of emergency use designation to
- 781 COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. Lancet
- 782 Infect Dis. 2021;21(4):e103-e9.
- 783 107. Greenland S. Basic methods for sensitivity analysis of biases. Int J
- 784 Epidemiol. 1996;25(6):1107-16.

785 **FIGURE LEGENDS**

- 786 **Figure 1**. Selection of studies for the systematic review
- 787
- **Figure 2**. VE point estimates from identified studies based on prior infection
- (Panel A), predominant circulating virus (Panel B) and vaccine type (Panel C).
- 790 Each point represents the VE point estimate. Estimates are jittered to enable
- visualisation. Black points represent the pooled VE estimate from meta-analysis
- with black lines representing the 95% confidence interval around the pooled
- estimate. Shaded area is the violin plot, showing the smoothed density of the VE
- 794 point estimates.
- 795

Figure 3. Pooled VE estimates against infection and severe disease by circulating

797 virus, vaccine types, and the inclusion or exclusion of participants with prior

798 COVID-19 infection from random-effect meta-analysis.

799

Figure 4. Predicted VE for a group of individuals based on the estimated ratio of

801 odds ratios (ROR) estimated from meta-regression, and the VE for the

802 individuals in the reference group. Panel A and B indicate predicted VE against

- 803 infection and severe disease, respectively. Prior COVID-19 infection, cumulative
- 804 incidence of cases before the study, and the incidence rate of cases during study
- are considered. Models adjusted for age group, type of vaccine, predominant
- 806 circulating virus, and enrolment criteria.
- 807
- 808

809





Factors		No. of estimates	VE range		VE (95% CI)	I^2
VE against infection						
Including participants with prior COVID-19 infection	on Excluded	96	(32, 98)	•	87 (85, 89)	100
	Included	77	(14, 98)	-	77 (72, 81)	100
Vaccine type	mRNA vaccines	126	(14, 98)	•	86 (84, 88)	100
	Adenovirus vector vaccines	41	(33, 96)	•	69 (64, 73)	100
	Inactivated virus vaccines	6	(44, 94)	●	67 (34, 84)	100
Predominant circulating virus	pre-Delta	92	(44, 98)	•	89 (87, 91)	99
	Delta	9	(32, 96)	— •	78 (58, 88)	100
	late-Delta	54	(33, 97)	•	79 (74, 82)	100
	Omicron	18	(14, 75)	-	52 (44, 59)	99
VE against severe disease						
Including participants with prior COVID-19 infection	on Excluded	40	(20, 99)	•	93 (91, 95)	98
	Included	53	(55, 100)	•	86 (83, 89)	99
Vaccine type	mRNA vaccines	73	(20, 100)	•	91 (89, 93)	99
	Adenovirus vector vaccines	16	(60, 95)	-	85 (79, 90)	98
	Inactivated virus vaccines	4	(56, 82)		71 (55, 81)	99
Predominant circulating virus	pre-Delta	35	(56, 100)	•	92 (89, 94)	97
	Delta	8	(65, 97)	-•-	87 (76, 93)	98
	late-Delta	42	(60, 99)	•	91 (88, 93)	99
	Omicron	8	(20, 86)	_	64 (52, 73)	84

